Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.
Marilin S KochMykola ZdiorukMichal O NowickiAlec M GriffithEstuardo AguilarLaura K AguilarBrian W GuzikFrancesca BaronePaul P TakGhazaleh TabatabaiJames A LedererE Antonio ChioccaSean LawlerPublished in: Journal for immunotherapy of cancer (2022)
Our data suggest that concurrent high-dose dexamethasone treatment may impair the efficacy of oncolytic viral immunotherapy of GBM, supporting the notion that dexamethasone use should be balanced between symptom control and impact on the therapeutic outcome.